# A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

> **NCT05804526** · PHASE1,PHASE2 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 82 (estimated)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** RC88
- **DRUG:** Sintilimab Injection

## Key facts

- **NCT ID:** NCT05804526
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-19
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804526, "A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05804526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*